Latest Breaking News On - செல்லுலார் மருந்தியல் - Page 1 : comparemela.com

Share this article Share this article CAMBRIDGE, Mass., March 9, 2021 /PRNewswire/  Q32 Bio, a biotechnology company developing therapeutics to restore healthy immune regulation, today announced the appointment of Jason Campagna, M.D., Ph.D. as Chief Medical Officer. Dr. Campagna brings more than 15 years of biotech and pharmaceutical experience to the Q32 Bio executive team during a critical growth and development period for the company.   We are delighted to welcome Jason to Q32 Bio as our Chief Medical Officer, said Mike Broxson, Chief Executive Officer of Q32 Bio. Jason provided critical guidance in the early days of the company, serving as a trusted clinical counselor as we ve advanced our groundbreaking tissue-targeted complement program ADX-097 towards the clinic. His extensive experience leading clinical development programs and strong background in academic research will complement our leadership team in our mission to restore immune homeostasis in patients with sev

United statesUnited kingdomJason campagnaMike broxsonMedicines companyBio incProgram at interceptIntercept pharmaceuticalsAtlas ventureUniversity of miamiCritical care at harvard medical schoolUniversity of pennsylvaniaHealth science lead of surgeryNeuroplasticty research groupCottage health systemChief medical